Spironolactone Tablet, Film Coated
Product Images NDC 55154-3556

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 55154-3556). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bag Label (96db5dee 7c01 4f96 8b1e 1fcd2103d0fe 00)

Bag Label (96db5dee 7c01 4f96 8b1e 1fcd2103d0fe 00)
This is a description of Spironolactone Tablets, USP with 25mg dosage. It is a blister pack of 10 tablets that should be stored at a temperature of 20 to 25 degrees Celsius. It is not intended for use by children as it is not child-resistant. The packaging contains information on how to use this drug, warnings, and prescribing information. The drug is manufactured in India by Cadia Healthcare Ltd and distributed in the USA by 2ydus Pharmaceuticals, Major Pharmaceuticals, and Cardinal Health.*
FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 01)

FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)

Image (B9a028ee 5720 4b9e A625 F7130aafd084 02)
This is a comparison of the effects of Spironolactone with Placebo on an unknown study population. The study involved 822 individuals who received Spironolactone and 841 individuals who received Placebo. The results were statistically significant (log-rank p < 0.001). The data is presented as a timeline of months ranging from 0 to 42. No further information is available.*
FDA Label Image

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)

Image (B9a028ee 5720 4b9e A625 F7130aafd084 03)
This appears to be a table of clinical trial data that shows different subgroups of patients with various characteristics such as age, sex, race, heart failure severity, and medication use. The table also displays the number of patients in each group and the level of benefit seen with Spironolactone treatment compared to a placebo.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.